It was previously maintained by the Dr. Reddy’s Laboratories.
Dubai: Neopharma, the US minor of Abu Dhabi has developed an antibiotic industrial facility and its relevant properties in Bristol, Tennessee. This activity is done under the possession assignment of Dr. Reddy Laboratories, Inc.
This facility continues providing and facilitate by the oral medicines consist of antibacterial goods for patients in the United State. Recently, Neopharma has run its five successful branches who facilitate the three continents that offer the services over 50 countries with 100 plus products.
“The acquisition follows similar acquisitions made in Japan, Brazil, and India and is a part of the global expansion drive for Neopharma, which is rapidly establishing itself as a global manufacturer of quality medications at affordable prices,” said Dr. B.R. Shetty, Chairman, Neopharma.
According to Suresh Kumar Nandiraju, Chief Operating Officer of Neopharma, said, “This acquisition allows us to enter the US penicillin-containing antibiotic market segment and marks our entry into the generic drug business in the US while providing opportunities to explore additional synergies with our other group companies.
The acquisition will help us leverage our expertise in beta-lactam manufacturing segment.” (Beta-lactam is a class of broad-spectrum antibiotics, consisting of all antibiotic agents that contain a beta-lactam ring in their molecular structures.)